Treatment of Factor-Xa Inhibitor-associated Bleeding with Andexanet Alfa or 4 Factor PCC: A Multicenter Feasibility Retrospective Study

BACKGROUND: There are no randomized trials comparing andexanet alfa and 4 factor prothrombin complex concentrate (4F-PCC) for the treatment of factor Xa inhibitor (FXa-I)-associated bleeds, and observational studies lack important patient characteristics. We pursued this study to demonstrate the fea...

Descripción completa

Detalles Bibliográficos
Autores principales: Singer, Adam J., Concha, Mauricio, Williams, James, Brown, Caitlin S., Fernandes, Rafael, Thode, Henry C., Kirchman, Marylin, Rabinstein, Alejandro A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Department of Emergency Medicine, University of California, Irvine School of Medicine 2023
Materias:
Nueurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527834/
https://www.ncbi.nlm.nih.gov/pubmed/37788035
http://dx.doi.org/10.5811/westjem.60587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527834/
https://www.ncbi.nlm.nih.gov/pubmed/37788035
http://dx.doi.org/10.5811/westjem.60587

Ejemplares similares